mt-1186
Amyotrophic Lateral Sclerosis
Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Tanabe Pharma Corporation
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05568615CT.gov Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS | — | Completed | — | — | — |
NCT05151471CT.gov Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS | — | Terminated | — | — | — |
NCT04569084CT.gov Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS | — | Terminated | — | — | — |
NCT04577404CT.gov Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) | — | Completed | — | — | — |
NCT04254913CT.gov Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy | — | Completed | — | — | — |
NCT04165824CT.gov Safety Study of Oral Edaravone Administered in Subjects With ALS | — | Completed | — | — | — |
NCT04176224CT.gov Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Amyotrophic Lateral Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| mt-1186 (this asset) | Tanabe Pharma Corporation | P3 | BB · 66 |
| Taurursodiol | Amylyx Pharmaceuticals Inc. | P3 | BBB |
| Tofersen | Biogen | P4 | BBB |
| Riluzole | AB Science | P4 | BB |
| Mexiletine | Bjorn Oskarsson, MD | P4 | BB |
| Diacetyl(N(4)-Methylthiosemicarbazonato) Copper (Ii) | Collaborative Medicinal Development Pty Limited | P2/3 | BB |
| Kns-760704 | Knopp Biosciences | P3 | BB |
| Mci-186 | Tanabe Pharma Corporation | P3 | BB |
| Autologous Mesenchymal Stromal Cells Secreting Neurotrophic Factors | Brainstorm-Cell Therapeutics | P3 | BB |
+42 more in the Amyotrophic Lateral Sclerosis cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. mt-1186 in Amyotrophic Lateral Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/mt-1186-amyotrophic-lateral-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →